JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the
safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for
Injection in subjects with IPF.